Prime Medicine (NASDAQ:PRME) Reaches New 52-Week High - Should You Buy?

Key Points

• Prime Medicine shares reached a new 52-week high of $5.17 during trading, marking a significant increase from the previous close of $4.65.
• Despite the stock's rally, Wall Street Zen downgraded Prime Medicine from a "hold" to a "sell" rating on September 2nd.
• The company is focused on developing one-time curative genetic therapies, utilizing their proprietary Prime Editing technology.

Shares of Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $5.17 and last traded at $5.05, with a volume of 2310676 shares trading hands. The stock had previously closed at $4.65.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of Prime Medicine from a "hold" rating to a "sell" rating in a research report on Tuesday, September 2nd.

Prime Medicine Price Performance

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.